InMed Pharmaceuticals Inc. Secures $5 Million Through Private Placement with Institutional Investor

Reuters06-25

<a href="https://laohu8.com/S/INM">InMed Pharmaceuticals Inc</a>. Secures $5 Million Through Private Placement with Institutional Investor

InMed Pharmaceuticals Inc., a pharmaceutical company focused on developing proprietary small molecule drug candidates, has announced a $5 million private placement priced at-the-market under Nasdaq rules. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares and short-term preferred investment options to purchase an equal number of common shares. The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The funds will support the development of InMed's pharmaceutical drug candidates, commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and general working capital. The offering is expected to close around June 25, 2025, pending customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 256740) on June 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2546217507?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-25 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546217507","market":"us","top_or_hot":-1,"title":"InMed Pharmaceuticals Inc. Secures $5 Million Through Private Placement with Institutional Investor","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/INM\">InMed Pharmaceuticals Inc</a>. Secures $5 Million Through Private Placement with Institutional Investor\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        InMed Pharmaceuticals Inc., a pharmaceutical company focused on developing proprietary small molecule drug candidates, has announced a $5 million private placement priced at-the-market under Nasdaq rules. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares and short-term preferred investment options to purchase an equal number of common shares. The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering. The funds will support the development of InMed's pharmaceutical drug candidates, commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and general working capital. The offering is expected to close around June 25, 2025, pending customary closing conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 256740) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InMed Pharmaceuticals Inc. Secures $5 Million Through Private Placement with Institutional Investor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInMed Pharmaceuticals Inc. Secures $5 Million Through Private Placement with Institutional Investor\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-25 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/INM\">InMed Pharmaceuticals Inc</a>. Secures $5 Million Through Private Placement with Institutional Investor\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        InMed Pharmaceuticals Inc., a pharmaceutical company focused on developing proprietary small molecule drug candidates, has announced a $5 million private placement priced at-the-market under Nasdaq rules. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares and short-term preferred investment options to purchase an equal number of common shares. The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering. The funds will support the development of InMed's pharmaceutical drug candidates, commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and general working capital. The offering is expected to close around June 25, 2025, pending customary closing conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 256740) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL7v3k6g:1","article_id":"2546217507","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546217507","pubTimestamp":1750852911,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InMed Pharmaceuticals Inc., a pharmaceutical company focused on developing proprietary small molecule drug candidates, has announced a $5 million private placement priced at-the-market under Nasdaq rules. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares and short-term preferred investment options to purchase an equal number of common shares. The securities were offered in a private placement under Section 4 of the Securities Act of 1933 and Regulation D. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The funds will support the development of InMed's pharmaceutical drug candidates, commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and general working capital. The offering is expected to close around June 25, 2025, pending customary closing conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","INM":"InMed Pharmaceuticals Inc"},"translate_title":"InMed Pharmaceuticals Inc.通过机构投资者私募获得500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INM":0.9},"content_text":"InMed Pharmaceuticals Inc. Secures $5 Million Through Private Placement with Institutional Investor\n    \n\n        InMed Pharmaceuticals Inc., a pharmaceutical company focused on developing proprietary small molecule drug candidates, has announced a $5 million private placement priced at-the-market under Nasdaq rules. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares and short-term preferred investment options to purchase an equal number of common shares. The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The funds will support the development of InMed's pharmaceutical drug candidates, commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and general working capital. The offering is expected to close around June 25, 2025, pending customary closing conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 256740) on June 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2546217507","isCrawlerRequest":true}